Commentary The PROGRESS trial three years later: time for more action, less distraction BMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7472.970 (Published 21 October 2004) Cite this as: BMJ 2004;329:970 Article Related content Metrics Responses Peer review Related articles Education And Debate The PROGRESS trial three years later: time for a balanced report of effectiveness Published: 21 October 2004; BMJ 329 doi:10.1136/bmj.329.7472.968 Correction The PROGRESS trial three years later: time for more action, less distraction (commentary) Published: 04 November 2004; BMJ 329 doi:10.1136/bmj.329.7474.1073-a Letter ASCOT: a tale of two treatment regimens Published: 27 October 2005; BMJ 331 doi:10.1136/bmj.331.7523.1022-b Letter Perindopril monotherapy and PROGRESS in Europe Published: 21 July 2005; BMJ 331 doi:10.1136/bmj.331.7510.235-b See more Sixty seconds on . . . 10 000 steps BMJ March 08, 2024, 384 q598; DOI: https://doi.org/10.1136/bmj.q598 Scarlett McNally: Enabling active travel can improve the UK’s health BMJ March 06, 2024, 384 q522; DOI: https://doi.org/10.1136/bmj.q522 Scarlett McNally: Boosting swimming for health and joy BMJ February 20, 2024, 384 q393; DOI: https://doi.org/10.1136/bmj.q393 Variability in blood pressure could help predict heart attack and stroke risk, researchers say BMJ February 09, 2024, 384 q363; DOI: https://doi.org/10.1136/bmj.q363 Scarlett McNally: Preventing obesity is different from curing it—and even more urgent BMJ January 23, 2024, 384 q134; DOI: https://doi.org/10.1136/bmj.q134 Cited by... Are Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Especially Useful for Cardiovascular Protection?Abstract Fulltext PDF ASCOT: a tale of two treatment regimens: Odds are that it's hypeAbstract Fulltext PDF Perindopril monotherapy and PROGRESS in EuropeAbstract Fulltext PDF